<DOC>
	<DOCNO>NCT00166725</DOCNO>
	<brief_summary>The present study provide information whether somatostatin analog , octreotide acetate , could inhibitory effect circulate chromogranin A . The demonstration antisecretory effect somatostatin analog could offer rationale large scale randomize study .</brief_summary>
	<brief_title>Effects Octreotide Acetate Circulating Levels Chromogranin A Advanced Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Male patient age &gt; 18 2 . ECOG performance status &lt; 3 3 . Patients metastatic prostate cancer currently receive 1st line hormonal therapy ( LHRH agonists surgical castration ) fail raise serum PSA 4 . Biochemical progression document three consecutively rise serum PSA measurement , separate least 2 week , last measurement 50 % great nadir PSA achieve last therapeutic maneuver ( i.e . first line hormonal therapy note ) 5 . Demonstrated tolerance test dose s.c. octreotide acetate injection Visit 1 6 . Elevated ( &gt; 40 U/L accord DAKO Elisa kit ) chromogranin A plasma level document least two consecutive measurement 7 . Liver function test &lt; 2.5 ULN , serum creatinine within normality 8 . Serum PSA ( 50 % increase value ) 4 ng/mL patient intact prostate &gt; 0.8 ng/mL post prostatectomy patient study entry 9 . Immediate history rise PSA &lt; 10 month 10 . Castrate level testosterone ( &lt; 30 ng/dL ) 11 . Life expectancy &gt; 6 month 12 . Signed informed consent prior initiation procedure 1 . Prior chemotherapy systemic anticancer therapy except LHRH agonist , and/or nonsteroidal antiandrogens ( eg , flutamide , bicalutamide nilandron ) 2 . Palliative radiotherapy le 6 week ( 42 day ) prior plan entry date 3 . Other investigational drug within past 28 day 4 . Longterm ( &gt; 3 month ) treatment proton pump inhibitor 5 . Uncontrolled blood hypertension 6 . Other malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer 7 . Patients another nonmalignant disease would confound evaluation primary endpoint prevent patient comply protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HRPC</keyword>
	<keyword>octreotide LAR</keyword>
	<keyword>CgA</keyword>
</DOC>